Christine Foster, PhD., is the Chief Business Officer of Stellular Bio. Prior to joining Stellular, Dr.Foster served as Chief Business Officer of Genetic Medicines at AlloyTherapeutics and CBO in residence at Alloy’s venture studio, 82VS. She has more than 30 years of industryexperience in the biopharmaceutical industry. Throughout her career, she has developed and executed strategic partnerships. At Alloy, she was lead negotiator for keyoligonucleotide collaborations with both Sanofi and Biogen. She has executed transactions in the field ofgenome editing with both Intellia Therapeutics and Metagenomi Therapeutics; sheplayed a critical role in the execution of deals with Affini-T Therapeutics,Ionis Pharmaceuticals, Regeneron Pharmaceuticals and Novartis; and establishednovel co-development and co-commercialization relationships with OnkTherapeutics, SparingVision, Kyverna Therapeutics and Avencell. Dr. Foster has led business development,alliance management and corporate development activities through key phases ofgrowth at Acceleron Pharma, Sunovion Pharmaceuticals, Inc., TevaPharmaceuticals, Wyeth (now Pfizer) and GlaxoSmithKline, among others. Trainedas a scientist, Christine earned a D.Phil. in pharmacology from the Universityof Oxford and completed post-doctoral fellowships at Brandeis University inneuroscience and the University of Massachusetts Medical School incardiovascular diseases.
